FDA.reportPublic FDA data

cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio]

RxCUI
2184147
RxNorm name
cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio]
Display name
cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio]
Full name
cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:19

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RECARBRIOIMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUSMerck Sharp & Dohme LLCbe32f468-738b-40df-a425-591e12f651592025-12-09Warnings, Adverse reactionsExact identifier
rxcui: 2184147

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
be32f468-738b-40df-a425-591e12f65159Recarbrio 500 MG / 500 MG / 250 MG Injection [PSN] · cilastatin 500 MG / imipenem 500 MG / relebactam 250 MG Injection [Recarbrio] [SBD] · Recarbrio 1.25 GM Injection [SY]311These highlights do not include all the information needed to use RECARBRIO safely and effectively. See full prescribing information for RECARBRIO. RECARBRIO ® (imipenem, cilastatin, and relebactam) for injection, for intravenous use Initial U.S. Approval: 201920251209